Advances in pharmacogenetics of anti-Parkinson's drugs treatment
- VernacularTitle:帕金森病药物治疗的遗传药理学研究进展
- Author:
Yingzi LIU
;
Jie LIU
;
Honghao ZHOU
- Publication Type:Journal Article
- Keywords:
Parkinson's disease;
genetic variation;
interindividual variability in drug response;
dopamine transporter;
dopamine receptor;
MAO-B
- From:
Chinese Pharmacological Bulletin
2003;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
Parkinson's disease(PD)is a neurodegenerative disease that predominantly affects the elderly.Dopamine mimicking drug is the mainstay in the treatment of Parkinson's disease.However,there is a large of interindividual variability in response to anti-Parkinson's disease drugs.It is thought that genetic variability in dopamine system genes is one of the important factors in determining interindividual variability in drug response.There are a lot of studies focused on the relationship between the risk of Parkinson's disease and genetic variations in domestic,while it is a lack of the pharmacogenetics study on Parkinson's disease.This review summarizes the relationship between the polymorphism of genes encoding dopamine transporter,dopamine-metabolizing enzymes and dopamine receptors and Parkinson's disease treatment.
